BI Asset Management Fondsmaeglerselskab’s Teva Pharmaceuticals TEVA Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Buy	54,001 +16,752	+45%	+$558K	0.01%	430
2026 Q1	$1.12M	Sell	37,249 -27,047	-42%	-$870K	0.01%	476
2025 Q4	$2.01M	Sell	64,296 -102,926	-62%	-$2.54M	0.02%	412
2025 Q3	$3.38M	Sell	167,222 -139,284	-45%	-$2.45M	0.03%	319
2025 Q2	$5.14M	Buy	306,506 +264,002	+621%	+$4.26M	0.05%	251
2025 Q1	$653K	Sell	42,504 -230,130	-84%	-$4.11M	0.01%	525
2024 Q4	$6.01M	Buy	+272,634	New	+$4.96M	0.06%	210
2024 Q2	–	Sell	-6,609	Closed	-$93K	–	737
2024 Q1	$93K	Buy	+6,609	New	+$83.3K	﹤0.01%	675
2020 Q4	–	Sell	-2,023	Closed	-$18K	–	477
2020 Q3	$18K	Buy	+2,023	New	+$21.4K	﹤0.01%	456

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's TEVA Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab increased its Teva Pharmaceuticals (TEVA) stake by 45% in Q2 2026, buying an estimated $558K and bringing the position to 54,001 shares worth $1.83M. The position accounts for 0.01% of the portfolio, ranked #430.

BI Asset Management Fondsmaeglerselskab first reported a position in TEVA in Q3 2020 and has held it in 9 quarters since. The position peaked at $6.01M in Q4 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

BI Asset Management Fondsmaeglerselskab held 54,001 shares of Teva Pharmaceuticals worth $1.83M as of Q2 2026.
BI Asset Management Fondsmaeglerselskab bought 16,752 Teva Pharmaceuticals shares in Q2 2026, an estimated $558K.
Teva Pharmaceuticals made up 0.01% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #430 holding.
BI Asset Management Fondsmaeglerselskab first reported a position in Teva Pharmaceuticals in Q3 2020 and has held it in 9 quarters since.
BI Asset Management Fondsmaeglerselskab's Teva Pharmaceuticals position peaked at $6.01M in Q4 2024.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.